FrancophonIA/ELRC3.0 huggingface dataset:
English: Among patients remaining in the study and treated with Simponi, DAS28 and HAQ DI responses were similar from week 104 through week 256.
Estonian: Uuringusse jäänud Simponiga ravitud patsientidel olid (DAS)28 ja HAQ-DI väärtuste paranemine 104. nädalast 256. nädalani sarnane.
English: Check the liquid in the viewing window.
Estonian: Kontrollige vaateaknast vedelikku.
English: • Check the expiration date and the security seal
Estonian: • kontrollige kõlblikkusaega ja turvariba;
English: • Cold sores
Estonian: • külmavillid
English: The card is aimed at both serving as a reminder to record the dates and outcomes of specific tests and to facilitate the patient sharing of special information with healthcare professional(s) treating the patient about ongoing treatment with the product.
Estonian: Selle abil on patsiendil lihtsam anda olulist infot selle ravimpreparaadiga toimuva ravi kohta teda raviva(te)le tervishoiutöötaja(te)le.
English: Malignancies and lymphoproliferative disorders
Estonian: Reproduktiivse süsteemi ja rinnanäärme häired
English: Check the liquid in the pre-filled syringe
Estonian: Kontrollige vedelikku pen-süstlis
English: A starting dose of 200 mg (the contents of 4 pre-filled syringes) followed by 100 mg (the contents of 2 pre-filled syringes) 2 weeks later.
Estonian: Algannus on 200 mg (4 süstli sisu), millele järgneb 100 mg (2 süstli sisu) 2 nädala pärast.
English: A starting dose of 200 mg (the contents of 2 pre-filled syringes) followed by 100 mg (the contents of 1 pre-filled syringe) 2 weeks later.
Estonian: Algannus on 200 mg (2 süstli sisu), millele järgneb 100 mg (1 süstli sisu) 2 nädala pärast.
English: Simponi 100 mg solution for injection in pre-filled pen.
Estonian: Simponi 100 mg süstelahus pen-süstlis.
English: Orange Priming Band
Estonian: Oranž ettevalmistusrõngas
English: Among patients remaining in the study and treated with Simponi, similar rates of patients showed no progression from baseline from week 104 through week 256.
Estonian: Sarnasel määral patsientidel ei täheldatud progresseerumist võrreldes lähteväärtusega 104. nädalast 256. nädalani uuringusse jäänud Simponiga ravitud patsientidel.
English: Patients were allowed to continue concomitant DMARD therapy with MTX, sulfasalazine (SSZ), and/or hydroxychloroquine (HCQ) during the study.
Estonian: Patsiendid randomiseeriti gruppidesse, kus neile manustati platseebot, Simponit annuses 50 mg või Simponit annuses 100 mg. Patsientidel lubati uuringu ajal jätkata samaaegset DMARD-ravi metotreksaadi, sulfasalasiini (SSZ) ja/või hüdroksüklorokviiniga (HCQ).
English: • Kidney infection
Estonian: • ninakõrvalkoobaste infektsioon
English: No dose adjustment is required in the elderly.
Estonian: Patsientide erirühmad Eakad (≥ 65-aastased) Eakatel ei ole annuse kohandamine vajalik.
English: Check security seal
Estonian: Kontrollige turvariba
English: Tell your doctor straight away if you get new or worsening symptoms of heart failure.
Estonian: Kui teil tekivad uued südamepuudulikkuse sümptomid või südamepuudulikkuse sümptomite halvenemine, rääkige sellest kohe oma arstile.
English: METHOD OF ADMINISTRATION
Estonian: Kontrollige süstekohta
English: • In patients weighing less than 80 kg, 50 mg (the contents of 1 pre-filled syringe) 4 weeks after your last treatment, then every 4 weeks thereafter.
Estonian: • Patsiendid kehakaaluga alla 80 kg: 50 mg (1 süstli sisu) 4 nädalat pärast teie viimast ravi, seejärel iga 4 nädala järel.
English: A starting dose of 200 mg (the contents of 2 pre-filled pens) followed by 100 mg (the contents of 1 pre-filled pen) 2 weeks later.
Estonian: Algannus on 200 mg (2 pen-süstli sisu), millele järgneb 100 mg (1 pen-süstli sisu) 2 nädala pärast.
English: • skin cancer (uncommon).
Estonian: • nahavähk (aeg-ajalt).
English: • Indigestion
Estonian: • unehäired
English: Simponi 50 mg solution for injection in pre-filled syringe.
Estonian: Simponi 50 mg süstelahus süstlis.
English: Set prescribed dose
Estonian: Seadistage teile määratud annus
English: Posology
Estonian: Üldskoor
English: The primary endpoint was the proportion of patients achieving ASAS 20 response at week 16.
Estonian: Uuringu esmane tulemusnäitaja oli patsientide hulk, kes saavutas 16. nädalal anküloseeriva spondüliidi hindamise uuringu grupis (ASAS) vastuse 20.
English: 0.25 mL 0.3 mL
Estonian: 0,25 ml
English: EU/1/09/546/008 (3 packs, each containing 1 pre-filled syringe)
Estonian: EU/1/09/546/008 (3 pakendit, millest igaühes on 1 süstel)
English: GENERAL CLASSIFICATION FOR SUPPLY
Estonian: Maksaensüümide taseme tõus
English: • In patients weighing 80 kg or more, 100 mg (the contents of 1 pre-filled syringe) 4 weeks after your last treatment, then every 4 weeks thereafter.
Estonian: • Patsiendid kehakaaluga 80 kg või rohkem: 100 mg (1 süstli sisu) 4 nädalat pärast teie viimast ravi, seejärel iga 4 nädala järel.
English: • Back of upper arms (if a caregiver is giving you the injection) Choose a different site within your preferred area for each injection.
Estonian: Iga kord valige süstimiseks erinev koht eelistatud piirkonnas.
English: • Hair loss
Estonian: • juuste kadu
English: • In patients weighing less than 80 kg, 50 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter.
Estonian: • Patsiendid kehakaaluga alla 80 kg: 50 mg (1 pen-süstli sisu) 4 nädalat pärast teie viimast ravi, seejärel iga 4 nädala järel.
English: • In patients weighing 80 kg or more, 100 mg (the contents of 2 pre-filled syringes) 4 weeks after your last treatment, then every 4 weeks thereafter.
Estonian: • Patsiendid kehakaaluga 80 kg või rohkem: 100 mg (2 süstli sisu) 4 nädalat pärast teie viimast ravi, seejärel iga 4 nädala järel.
English: • Breast disorders
Estonian: • neerude häired
English: 0.15 mL 0.2 mL
Estonian: 0,15 ml
English: MTX Placebo
Estonian: Platseebo + metotreksaat
English: Simponi 100 mg solution for injection in pre-filled syringe 1 mL solution in a pre-filled syringe (Type 1 glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex).
Estonian: 1 ml lahust (I tüüpi klaasist) süstlis, millele on kinnitatud nõel (roostevabast terasest) ja nõelakate (kummist, mis sisaldab lateksit).
English: A starting dose of 200 mg (the contents of 4 pre-filled pens) followed by 100 mg (the contents of 2 pre-filled pens) 2 weeks later.
Estonian: Algannus on 200 mg (4 pen-süstli sisu), millele järgneb 100 mg (2 pen-süstli sisu) 2 nädala pärast.
English: Simponi 50 mg solution for injection in pre-filled syringe 0.5 mL solution in a pre-filled syringe (Type 1 glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex).
Estonian: 0,5 ml lahust (I tüüpi klaasist) süstlis, millele on kinnitatud nõel (roostevabast terasest) ja nõelakate (kummist, mis sisaldab lateksit).
English: Simponi 50 mg solution for injection golimumab
Estonian: Simponi 50 mg süstitav ravim golimumab s.c.
English: What Simponi looks like and contents of the pack Simponi is supplied as solution for injection in a single-use pre-filled pen, VarioJect.
Estonian: Simponit tarnitakse süstelahusena ühekordseks kasutamiseks mõeldud pen-süstlis (VarioJect).
English: Ankylosing spondylitis
Estonian: Anküloseeriv spondüliit
English: Pack size of 1 pre-filled pen.
Estonian: Pakendis on 1 pen-süstel.
English: Week 24 5% 20%*
Estonian: 24. nädal 52. nädal
English: Simponi 100 mg solution for injection in pre-filled pen 1 mL solution in a pre-filled syringe (Type 1 glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex) in a pre-filled pen.
Estonian: 1 ml lahust (I tüüpi klaasist) süstlis, millele on kinnitatud nõel (roostevabast terasest) ja nõelakate (kummist, mis sisaldab lateksit), mis paikneb pen-süstlis.
English: • In patients weighing 80 kg or more, 100 mg (the contents of 2 pre-filled pens) 4 weeks after your last treatment, then every 4 weeks thereafter.
Estonian: • Patsiendid kehakaaluga 80 kg või rohkem: 100 mg (2 pen-süstli sisu) 4 nädalat pärast teie viimast ravi, seejärel iga 4 nädala järel.
English: Simponi 100 mg solution for injection golimumab
Estonian: Simponi 100 mg süstitav ravim golimumab s.c.
English: Simponi 50 mg solution for injection in pre-filled pen 0.5 mL solution in a pre-filled syringe (Type 1 glass) with a fixed needle (stainless steel) and a needle cover (rubber containing latex) in a pre-filled pen.
Estonian: 0,5 ml lahust (I tüüpi klaasist) süstlis, millele on kinnitatud nõel (roostevabast terasest) ja nõelakate (kummist, mis sisaldab lateksit), mis paikneb pen-süstlis.
English: • In patients weighing 80 kg or more, 100 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter.
Estonian: • Patsiendid kehakaaluga 80 kg või rohkem: 100 mg (1 pen-süstli sisu) 4 nädalat pärast teie viimast ravi, seejärel iga 4 nädala järel.
English: Simponi 50 mg solution for injection in pre-filled syringe golimumab
Estonian: Simponi 50 mg süstelahus süstlis Golimumab
English: Check injection site
Estonian: Kontrollige vedelikku
English: Malignancies
Estonian: Nahavähid
English: Patients were randomised to receive placebo, Simponi 50 mg, or Simponi 100 mg.
Estonian: Patsiendid randomiseeriti gruppidesse, kus neile manustati järgmisi ravimikombinatsioone: platseebo + metotreksaat, Simponi 50 mg + metotreksaat, Simponi 100 mg + metotreksaat või Simponi 100 mg + platseebo.
English: PRE-FILLED PEN FOR PAEDIATRIC USE LABEL
Estonian: LASTEL KASUTAMISEKS ETTE NÄHTUD PEN-SÜSTLI SILT
English: Simponi 100 mg solution for injection in pre-filled syringe.
Estonian: Simponi 100 mg süstelahus süstlis.
English: Simponi 100 mg solution for injection in pre-filled syringe golimumab
Estonian: Simponi 100 mg süstelahus süstlis Golimumab
English: EU/1/09/546/004 (3 packs, each containing 1 pre-filled syringe)
Estonian: EU/1/09/546/004 (3 pakendit, millest igaühes on 1 süstel)
English: 0.35 mL 0.4 mL
Estonian: 0,35 ml
English: PRE-FILLED SYRINGE LABEL
Estonian: Teie pen-süstli ülevaade
English: • Gall stones
Estonian: • villid nahal
English: One 1 mL pre-filled pen contains 100 mg of golimumab.
Estonian: Üks 1 ml pen-süstel sisaldab 100 mg golimumabi.
English: 1.1 Prior to Simponi treatment:
Estonian: Enne ravi Simponiga
English: At week 48,
Estonian: 14. nädal
English: If you use more Simponi than you should
Estonian: Kui te unustate Simponit kasutada
English: It is used after at least one other treatment has failed;
Estonian: Ravimit kasutatakse pärast seda, kui vähemalt üks muu ravi on ebaõnnestunud;
English: Treatment may continue until the disease gets worse.
Estonian: Ravi tohib jätkata kuni haiguse süvenemiseni.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Hycamtin on 12 November 1996.
Estonian: Euroopa Komisjon andis Hycamtini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 12. novembril 1996.
English: This is repeated every 21 days for six courses or until the disease gets worse.
Estonian: Seda korratakse iga 21 päeva järel 6 kuurina või kuni haiguse süvenemiseni.
English: The full EPAR for Hycamtin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Hycamtini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Hycamtin topotecan
Estonian: Hycamtin topotekaan
English: What measures are being taken to ensure the safe and effective use of Hycamtin?
Estonian: Mis meetmed võetakse, et tagada Hycamtini ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Hycamtin is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Hycamtini võimalikult ohutu kasutamine.
English: It is used when giving the original treatment again is not recommended.
Estonian: Ravimit kasutatakse juhul, kui algset ravi ei ole soovitatav korrata.
English: The main measure of effectiveness was the number of patients whose tumours responded to treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle kasvaja allus ravile.
English: Other information about Hycamtin
Estonian: Muu teave Hycamtini kohta
English: The most common side effects with Hycamtin (seen in more than 1 patient in 10) are neutropenia (low white blood cell counts), febrile neutropenia (neutropenia with fever), thrombocytopenia (low platelet counts), anaemia (low red blood cell counts), leucopenia (low white blood cell counts), nausea (feeling sick), vomiting and diarrhoea (all of which may be severe), constipation, abdominal (tummy) pain, mucositis (mouth sores), alopecia (hair loss), loss of appetite (which may be severe), infections, pyrexia (fever), asthenia (weakness) and fatigue (tiredness).
Estonian: Kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on neutropeenia (vere valgeliblede vähesus), palavikku tekitav neutropeenia, trombotsütopeenia (vereliistakute vähesus), aneemia (vere punaliblede vähesus), leukopeenia (vere valgeliblede vähesus), iiveldus, oksendamine, kõhulahtisus (võivad kõik olla rasked), kõhukinnisus, kõhuvalu, mukosiit (suuhaavandid), alopeetsia (juuste väljalangemine), isutus (võib olla raske), infektsioonid, palavik, asteenia ja väsimus.
English: It was as effective as the standard combination chemotherapy.
Estonian: Selle efektiivsus oli sama kui standardsel keemiaravi kombinatsioonil.
English: This is a summary of the European public assessment report (EPAR) for Hycamtin.
Estonian: See on ravimi Hycamtin Euroopa avaliku hindamisaruande kokkuvõte.
English: Hycamtin has also been studied in three main studies in 656 patients with relapsed small cell lung cancer.
Estonian: Hycamtini on uuritud ka 3 põhiuuringus 656 patsiendil, kelle väikerakk-kopsuvähk oli taastunud.
English: It is available as a powder to be made up into a solution for infusion (drip) into a vein and as capsules (0.25 and 1 mg).
Estonian: Seda turustatakse pulbrina, millest valmistatakse infusioonilahus (tilgutamiseks veeni), ja kapslitena (0,25 mg ja 1 mg).
English: • metastatic cancer of the ovary (when the cancer has spread to other parts of the body).
Estonian: • metastaasidega munasarjavähk (vähk on levinud organismis ka mujale).
English: The CHMP decided that Hycamtin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Hycamtini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Treatment with Hycamtin should only be given under the supervision of a doctor experienced in the use of chemotherapy.
Estonian: Ravi Hycamtiniga peab toimuma üksnes keemiaravi kasutamises kogenud arsti järelevalve all.
English: Three studies were ‘open', meaning that the medicine was not compared to any other treatment and the patients knew that they were receiving Hycamtin.
Estonian: Kolm uuringut olid avatud uuringud, milles Hycamtini muude ravimitega ei võrreldud ja kus patsiendid teadsid, et nad saavad Hycamtini.
English: In the main study, 21% of the patients who received Hycamtin (23 out of 112) responded to treatment, compared with 14% of the paclitaxel patients (16 out of 114).
Estonian: Põhiuuringus allus ravile 21% Hycamtini saanud patsientidest (23 patsienti 112st), seevastu paklitakseeli saanud patsientidest allus ravile 14% (16 patsienti 114st).
English: In cervical cancer, patients receiving the combination of Hycamtin and cisplatin survived an average of 9.4 months, compared with 6.5 months for the patients who received cisplatin only.
Estonian: Emakakaelavähiga patsientidest oli Hycamtini ja tsisplatiini kombinatsiooni saanud patsientide keskmine elulemus 9,4 kuud ja ainult tsisplatiini saanud patsientidel 6,5 kuud.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Hycamtin, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Hycamtini omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In ovarian cancer, the studies showed the effectiveness of Hycamtin, with an overall response rate of about 16%.
Estonian: Munasarjavähi uuringud näitasid Hycamtini efektiivsust: üldine ravivastuse määr oli ligikaudu 16%.
English: The effectiveness was measured by looking at overall survival.
Estonian: Efektiivsust mõõdeti üldise elulemuse põhjal.
English: For both ovarian and lung cancer, Hycamtin is given every day for five days with a three-week interval between the start of each course.
Estonian: Nii munasarja- kui ka kopsuvähi korral manustatakse Hycamtini iga päev 5 päeva jooksul, jättes ravikuuride alustamispäevade vahele 3-nädalase intervalli.
English: Hycamtin must not be used in patients who are breast-feeding, or in patients who have severe bone marrow depression (low white blood cell and platelet counts) before treatment.
Estonian: Hycamtini ei tohi kasutada imetavad patsiendid ega patsiendid, kellel on enne ravi luuüdi raske depressioon (leukotsüütide (valgeliblede) ja trombotsüütide (vereliistakute) vähesus).
English: What is Hycamtin?
Estonian: Mis on Hycamtin?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Hycamtin.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Hycamtin read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Hycamtiniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Hycamtin as an infusion has been studied in more than 480 women with ovarian cancer who had failed one treatment with platinum-containing cancer medicines.
Estonian: Hycamtini infusioonina kasutamist on uuritud rohkem kui 480-l munasarjavähiga naisel, kellel oli üks plaatinat sisaldavate vähiravimite kuur ebaõnnestunud.
English: It is also used together with cisplatin (another cancer medicine) to treat women with cancer of the cervix, when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (has spread beyond the cervix).
Estonian: Hycamtini kasutatakse ka koos tsisplatiiniga (samuti vähiravim) emakakaelavähi raviks naistel, kellel vähk on pärast kiiritusravi taastunud, ning samuti kaugelearenenud haiguse korral (on levinud emakakaelast kaugemale).
English: For the full list of all side effects and restrictions with Hycamtin, see the package leaflet.
Estonian: Hycamtini kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The dose of Hycamtin to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Estonian: Kasutatav Hycamtini annus sõltub ravitavast vähiliigist ning patsiendi kaalust ja pikkusest.
English: One study compared Hycamtin capsules with symptom control alone and another compared Hycamtin as an infusion with cyclophosphamide, doxorubicin and vincristine (a standard combination of chemotherapy).
Estonian: Ühes uuringus võrreldi Hycamtini kapsleid sümptomaatilise raviga, teises võrreldi Hycamtini infusiooni tsüklofosfamiidi, doksorubitsiini ja vinkristiiniga (standardne keemiaravi kombinatsioon).
English: For lung cancer, Hycamtin can be given as an infusion or, for adults, as capsules.
Estonian: Kopsuvähi raviks võib Hycamtini manustada infusioonina või täiskasvanud patsientidel kapslitena.
English: In lung cancer, looking at the results obtained in all three studies, the response rate was 20% (480 patients received Hycamtin).
Estonian: Kopsuvähiga patsientidel oli kõigi kolme uuringu kokkuvõttes ravivastuse määr 20% (480 patsienti, kes said Hycamtini).
English: Hycamtin is a cancer medicine that contains the active substance topotecan.
Estonian: Hycamtin on vähiravim, mis sisaldab toimeainena topotekaani.
English: Hycamtin also affects non-cancer cells, which causes side effects.
Estonian: Hycamtin mõjutab ka muid rakke peale vähirakkude ning see põhjustab kõrvalnähte.
English: What is the risk associated with Hycamtin?
Estonian: Mis riskid Hycamtiniga kaasnevad?
English: Why has Hycamtin been approved?
Estonian: Miks Hycamtin heaks kiideti?
English: The fourth study involved 226 women, and compared Hycamtin with paclitaxel (another cancer medicine).
Estonian: Neljandas uuringus osales 226 naist ja selles võrreldi Hycamtini toimet paklitakseeli (samuti vähiravim) toimega.
English: When used with cisplatin in cervical cancer, Hycamtin is given as an infusion on days 1, 2 and 3 (with cisplatin given on day 1).
Estonian: Kasutamisel koos tsisplatiiniga emakakaelavähi raviks manustatakse Hycamtini infusioonina ravi 1., 2. ja 3. päeval (manustades tsisplatiini 1. päeval).
English: Hycamtin as an infusion has been studied in 293 women with advanced cervical cancer, where the effectiveness of a combination of Hycamtin and cisplatin was compared with that of cisplatin alone.
Estonian: Hycamtini kasutamist infusioonina on uuritud 293-l kaugelearenenud emakakaelavähiga naisel, võrreldes Hycamtini ja tsisplatiini kombinatsiooni mõju ainult tsisplatiini mõjuga.
English: When Hycamtin is used on its own for ovarian cancer, it is given by intravenous infusion over 30 minutes.
Estonian: Hycamtini kasutamisel ainsa ravimina munasarjavähi raviks manustatakse seda veeniinfusioonina 30 minuti jooksul.
English: The third study compared Hycamtin given as an infusion and as capsules.
Estonian: Kolmandas uuringus võrreldi Hycamtini mõju selle kasutamisel kapslite ja infusioonina.
English: For full details, see the summary of product characteristics, also part of the EPAR.
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: The effectiveness was measured by looking at survival or response rates.
Estonian: Efektiivsust mõõdeti elulemuse või ravivastuse määraga.
English: The active substance in Hycamtin, topotecan, is a cancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Estonian: Hycamtini toimeaine topotekaan on topoisomeraasi inhibiitorite rühma kuuluv vähiravim.
English: Doses of Hycamtin may need to be adjusted or treatment delayed, depending on side effects.
Estonian: Sõltuvalt kõrvalnähtudest võib olla vaja Hycamtini annuseid muuta või ravi edasi lükata.
English: How does Hycamtin work?
Estonian: Kuidas Hycamtin toimib?
English: Infusions should be carried out in a specialised cancer ward.
Estonian: Infusioone tuleb teha onkoloogiaosakonnas.
English: What is Hycamtin used for?
Estonian: Milleks Hycamtini kasutatakse?
English: How is Hycamtin used?
Estonian: Kuidas Hycamtini kasutatakse?
English: How has Hycamtin been studied?
Estonian: Kuidas Hycamtini uuriti?
English: What benefit has Hycamtin shown during the studies?
Estonian: Milles seisneb uuringute põhjal Hycamtini kasulikkus?
English: Compared with symptom control alone, Hycamtin prolonged survival by
Estonian: Võrreldes sümptomaatilise raviga pikendas Hycamtin elulemust 12 nädala võrra.
English: Hycamtin is used on its own to treat patients with:
Estonian: Hycamtini kasutatakse ainsa ravimina järgmiste vähivormide raviks:
English: Hycamtin given as capsules was as effective as Hycamtin given as an infusion.
Estonian: Kapslitena ja infusioonina manustatud Hycamtini mõju oli sama.
English: The European Commission issued a decision on 10 September 2012.
Estonian: Euroopa Komisjon tegi otsuse 10. septembril 2012.
English: What is Zinacef?
Estonian: Mis on Zinacef?
English: Zinacef is marketed in all EU Member States (except Germany, Latvia, Slovakia and Spain), as well as Iceland and Norway.
Estonian: Zinacefi turustatakse kõikides ELi liikmesriikides (välja arvatud Saksamaal, Lätis, Slovakkias ja Hispaanias) ning Islandil ja Norras.